Archived Insight | May 12, 2021

Medical Stop-Loss Insurance Checklist

Segal works with hundreds of group medical plans to help them get the medical stop-loss insurance that best meets their needs.

We compiled this stop-loss insurance checklist you can use to make sure you’re getting the right coverage for your plan.

Get the Checklist

medical stop loss insurance Download Now

Highlights from the checklist

The checklist can assist you with:

  • Determining the adequacy of your current stop-loss coverage by reviewing your actual claims data
  • Setting up monthly high-cost claim reporting
  • Implementing third-party audit protocols for any known inpatient hospital or drug claim with $100,000 or more in submitted claims pending
  • Obtaining current plan coverage documents and amendments annually
  • Requesting bids every two to three years to make sure you’re getting the best possible deal on your stop-loss coverage

There are many other important points covered in the full checklist. 

Questions about medical stop-loss insurance?

To discuss the adequacy and competitiveness of your plan’s medical stop-loss insurance, get in touch. 

See more insights

Young Couple Going Over Financial Documents At Home

Final Rule on Healthcare Transparency in Coverage

Learn how the Transparency in Coverage final rule affects disclosure requirements, price comparison tools and implementation planning.

Health, Compliance, Healthcare Industry, Higher Education, Multiemployer Plans, Public Sector, Corporate

Read Full Insight

Asian Female Pharmacist Uses Computer To Check Inventory For A Drug

Designing and Negotiating Affordable Pharmacy Benefits

Learn how health plan sponsors can improve pharmacy benefit value through PBM contracting, formulary management and clinical oversight.

Health, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Corporate, Pharmaceutical, Healthcare Cost Management

Read Full Insight

Man Self Injecting GLP 1 Weight Loss Medication Pen At Home

GLP-1s Have Disrupted the Market for Other Diabetes Drugs

Segal’s SHAPE data shows how rising GLP-1 use coincided with declines in insulin, Metformin and DPP-4 inhibitor use.

Health, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Corporate, Pharmaceutical

Read Full Insight

This page is for informational purposes only and does not constitute legal, tax or investment advice. You are encouraged to discuss the issues raised here with your legal, tax and other advisors before determining how the issues apply to your specific situations.